Pushing the boundaries of
innovation in oncology.
innovation in oncology.
Pushing the boundaries of
innovation in oncology.
innovation in oncology.
About
There is more innovation in cancer research today than ever before. Many of these efforts are disjointed and silo-ed and as a result often do not reach their full potential. If we can capture that potential, there is great opportunity for cancer patients.
Cullinan uniquely applies open innovation to the development of scientific oncology assets. Our approach breaks down silos, encourages new ways of thinking and collaboration, and ultimately turns ideas and inspiration into novel executable therapeutic concepts. Through both internal and external means, we seek to develop first-in-class or best-in-class assets that have the potential to significantly improve the lives of those living with cancer.
Drug development through
the prism of modern-day
portfolio management.
the prism of modern-day
portfolio management.
Our Approach
Cullinan was formed to advance a growing portfolio of innovative, early-stage assets by capitalizing on the latest scientific breakthroughs. The company is structured as a unique hybrid model that brings together certain aspects of an investment firm with a true operating company. As a result, we think about capital allocation and risk as much as we think about in-vivo results or clinical trial design.
- Access to the world’s earliest stage oncology research through relationships with MPM Capital, academia, and pharma
- Portfolio diversification across platforms, mechanisms and modalities
- Led by a team of veteran oncology researchers, biopharma executives, and experienced entrepreneurs
Team
At the core of any great company is its people. The Cullinan team is a group of accomplished professionals that share a vision for eradicating cancer.
Board of Directors
Investors
Lori has more than 30 years of experience in providing administrative support to ensure efficient operation of the office. Prior to joining Cullinan Oncology Lori worked at UBS Financial, Barclays and Merrill Lynch.
Prior to joining Cullinan, Natalia served as a Clinical Trial Manager at Infinity Pharmaceuticals where she was the global operational lead for MARIO-275, their phase II trial in urothelial cancer. Previously, she was at Unum Therapeutics for three years where she helped bring their first-in-human ACTR platform technology to the clinic for both hematologic and solid tumor malignancies. She also led Unum’s long-term observational trial during her tenure. Natalia began her career on the CRO side of the industry at Harvard Clinical Research Institute working on trials in Phases I-III in a wide range of indications.
Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Cullinan Oncology, Jeff most recently served as CFO at Amylyx Pharmaceuticals where he established the company’s Finance and Accounting operations and oversaw the successful completion of a Series B financing. Jeff joined Amylyx after serving as a Vice President at BlueRock Therapeutics, an engineered cell and gene therapy company, where he played a leading role in building out the finance function and supporting its sale to Bayer AG in a transaction that valued BlueRock up to $1 billion. Previously, Jeff held corporate finance and strategy roles at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, and in Healthcare Investment Banking and Equity Capital Markets at RBC Capital Markets and Credit Suisse. 
Most recently, Kerry was Director of Discovery and Translational Biology, and led multiple oncology programs. She held prior positions at both Aveo and Wyeth, and her drug development background spans preclinical to Phase 2 assets and includes biologics, ADC’s, and small molecules.
Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics (NASDAQ:MGNX), where he led the company’s evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. This included the translation of ten new molecules into the clinic, including early phase and/or proof-of-concept studies with bispecific molecules, checkpoint inhibitors, Fc-optimized antibodies and antibody drug conjugates, as well as the design and execution of registration-directed studies.
Erica is an Executive Assistant and Office Supervisor at Cullinan Oncology.
